According to Tonghe Pharmaceutical's announcement, Hangzhou Xia Shenghe, Shen Xiong, and Zhejiang Heze, shareholders of the participating company Hangzhou Boya, plan to transfer 1.9252%, 0.385%, and 3.8504% of their shares to Pang Zeyuan, an affiliate of the company's actual controller, at transfer prices of 1,7322.67 million yuan, 346.53 million yuan, and 3.46536 million yuan respectively. The company decided to relinquish priority purchasing rights. The matter constituted a related transaction and did not constitute a major asset restructuring. On July 21, 2026, the board of directors of the company reviewed and passed the bill, and the independent directors agreed. Before and after the transfer was completed, the company's shareholding ratio in Hangzhou Boya remained unchanged, and there was no significant impact on the company's finance and operations.

According to Tonghe Pharmaceutical's announcement, Hangzhou Xia Shenghe, Shen Xiong, and Zhejiang Heze, shareholders of the participating company Hangzhou Boya, plan to transfer 1.9252%, 0.385%, and 3.8504% of their shares to Pang Zeyuan, an affiliate of the company's actual controller, at transfer prices of 1,7322.67 million yuan, 346.53 million yuan, and 3.46536 million yuan respectively. The company decided to relinquish priority purchasing rights. The matter constituted a related transaction and did not constitute a major asset restructuring. On July 21, 2026, the board of directors of the company reviewed and passed the bill, and the independent directors agreed. Before and after the transfer was completed, the company's shareholding ratio in Hangzhou Boya remained unchanged, and there was no significant impact on the company's finance and operations.